Behavioral Activation, Nutrition, and Activity Intervention

Participants will complete the Patient Health Questionnaire - 9 (PHQ-9) at baseline and at the Week 16 follow up visit. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV. Where total scores of 5 to 9 = mild, 10 to 14 = moderate, 15 to 19 = moderately severe, and 20 = severe depression.

Participants will complete the University of California, Los Angeles (UCLA) Loneliness Questionnaire (Version 3) at baseline and at the Week 16 follow up visit. This is a 20-item scale designed to measure one's subjective feelings of loneliness. Participants rate each item on a scale where 1 = Never, 2 = rarely, 3 = sometimes and 4 = Often. Total scores of 20 - 40 are considered low to moderate, 40 - 60 are considered moderate to high, and score above 60 are considered high in terms of loneliness.

Participants will complete the Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Scale at Baseline and at the Week 16 follow up visit, to measure social isolation. Total scores of 0.5 - 1.0 SD (standard deviation) worse than the mean = mild symptoms/impairment, scores of 1.0 - 2.0 SD worse than the mean = moderate symptoms/impairment, and scores 2.0 SD or more worse than the mean = severe symptoms/impairment.

Participants will be given a wearable sensor device to track movements. Physical activity will be assessed using number of daily steps walked measured by the wearable sensor.

Participants will be given a wearable sensor device to track movements. Physical inactivity will be assessed using minutes of sedentary time measured by a wearable sensor.

TST will be measured by a wearable sensor, from baseline to the final week of the intervention.

SE will be measured by a wearable sensor, from baseline to the final week of the intervention.

SOL will be measured by a wearable sensor, from baseline to the final week of the intervention.

Participants will complete the 18-item Mini Nutritional Assessment (MNA®) at the baseline visit. The MNA® is a screening tool to help identify elderly persons who are malnourished or at risk of malnutrition. A score of 12 or greater indicates the person is well nourished and needs no further intervention. A score of 8-11 indicates the person is at risk of malnutrition. A score of 7 or less indicates the person is malnourished.

Participants will complete the Generalized Anxiety Disorder scale-7 (GAD-7) at the baseline and week 16 follow up visit. It is a seven-item diagnostic tool, based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria, for identifying likely cases of GAD. Where a score of 0 - 4 = minimal anxiety, 5 - 9 = mild anxiety, 10 - 14 = moderate anxiety, and a score greater than 15 = severe anxiety.

Participants will complete the Late-Life Function & Disability Instrument (Late-Life FDI). It is designed to assess and be responsive to meaningful change in two distinct outcomes: function and disability.

Scores approaching 100 signify high levels in ability to perform discrete actions and activities (without assistance), scores approaching 0 signify low levels in ability to perform discrete actions and activities (without assistance).

Participants will complete the Yale Physical Activity Survey. This survey was developed to determine the type, amount and patterning of physical activity/exercise in older adults. The tool is composed of two sections - (1) amount of physical activity/exercise performed during a typical week in the past month and (2) activities performed in the past month. In section one, participants are handed a checklist of activity categories (work, exercise, and recreational activities) and are asked how often during the past week they performed a particular activity from each category. Higher scores indicate high levels of physical activity, while lower score indicate lower activity levels or more sedentary lifestyle.

A 9-item instrument with possible scores ranging from 0 (no perceived stigma) to 45 (high perceived stigma). The HIV Stigma Scale was designed to measure the perception of stigma by those who are HIV infected.

Self reported chronological date of birth.

Self reported racial or ethnic background.

Characterization of male or female based on their biological characteristics when they were born.

Characterization of male or female based on their self-identified gender.

Participants self reported sexual orientation.

Self reported completed level of schooling or degree obtained.

A lab measurement of immune function in patients living with HIV.

Viral load is a marker of response to antiretroviral therapy (ART).

BMD is expressed by the mass of calcium hydroxyapatite present in a given area or volume of bone in a unit of mass/area (g/cm2) or mass/volume (g/cm3), respectively.

"-2.5 and below" = "Osteoporosis" " -1.1 to -2.5" = "Osteopenia".

Participants self reported smoking usage.

Measurement of the force of blood against the arterial walls, to evaluate the impact of interventions on cardiovascular health.

Lipid panel measures all three cholesterol and triglyceride/fat in the blood to assess for CVD risk. >240 mg/dl = High total cholesterol; 130 - 159 md/dl = High LDL; <40 mg/dl = Low HDL; >150 mg/dl = High TG.

Assessing participants for the presence or absence of diabetes.

Assessing whether participants are using aspirin.

Assessing whether participants are using statin medications.

10-year risk calculated using the cardiovascular disease risk measures listed to help decide Statin or Aspirin prescription.

Urine analysis detects protein and blood in urine, supposed to be filtered by kidney, where Abnormal = "Risk for renal disease"; >30 = "Kidney disease".

Measures kidney performance based on the amount of blood filtered per minute. Abnormal = "Risk for renal disease"; <60 = "Kidney disease"; <=15 = "Kidney failure".